Sarepta Therapeutics, Inc. - Common Stock (SRPT)
17.94
-0.29 (-1.59%)
NASDAQ · Last Trade: Aug 11th, 8:15 PM EDT
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Sarepta securities between June 22,2023 and June 24, 2025, both dates inclusive (the “Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · August 11, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 11, 2025
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) between June 22, 2023 and June 24, 2025, inclusive.
By Bernstein Liebhard LLP · Via GlobeNewswire · August 11, 2025
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · August 9, 2025
NEW YORK - August 8, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
Via TheNewswire.com · August 8, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 8, 2025
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · August 7, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 7, 2025
NEW YORK - August 7, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
Via TheNewswire.com · August 7, 2025
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2025.
By Sarepta Therapeutics, Inc. · Via Business Wire · August 6, 2025
NEW YORK - August 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
Via TheNewswire.com · August 6, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 6, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ:SRPT) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Sarepta securities between June 22,2023 and June 24, 2025, both dates inclusive (the “Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Bragar Eagel & Squire · Via GlobeNewswire · August 5, 2025
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · August 5, 2025
NEW YORK - August 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
Via TheNewswire.com · August 5, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 5, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 4, 2025
NEW YORK - August 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
Via TheNewswire.com · August 4, 2025
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
By Bernstein Liebhard LLP · Via GlobeNewswire · August 4, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta (SRPT) or PetCo (WOOF) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · August 2, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 1, 2025
NEW YORK - August 1, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
Via TheNewswire.com · August 1, 2025
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · August 1, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 31, 2025
NEW YORK - July 31, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) of a class action securities lawsuit.
Via TheNewswire.com · July 31, 2025